Daily Medication Pearl: Finerenone (Kerendia)
Finerenone (Kerendia) is indicated to reduce the risk of sustained eGFR decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease.
Medication Pearl of the Day: Finerenone (Kerendia)
Indication: Finerenone (Kerendia) is a non-steroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease associated with type 2 diabetes.
- Dosing: The recommended starting dosage is 10 mg or 20 mg orally once daily based on eGFR and serum potassium thresholds.
- Dosage forms: Tablets 10 mg and 20 mg.
- Adverse events: Adverse reactions occurring in ≥ 1% of patients on finerenone and more frequently than placebo are hyperkalemia and hypotension.
- Mechanism of action: Finerenone is a nonsteroidal, selective antagonist of the mineralocorticoid receptor (MR), which is activated by aldosterone and cortisol and regulates gene transcription. Finerenone blocks MR mediated sodium reabsorption and MR overactivation in both epithelial (e.g., kidney) and nonepithelial (e.g., heart, and blood vessels) tissues. MR overactivation is thought to contribute to fibrosis and inflammation.
- Manufacturer: Bayer Pharmaceuticals